Product information and disease descriptionPlace of product in therapyApproaches to treatment
Current treatment options and standard of care
86 evidence topics · 65 sources
Azetukalner (XEN1101)
Focal onset seizures
- Manufacturer
- Xenon Pharmaceuticals
- Regulatory submission
- NDA submitted September 2026
- Launch
- Not announced
- Last updated